• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Consumer Cyclical·1737.TW
Share

Taiyen Biotech Co., Ltd. Stocks

NT$ 31.95Last Updated 24.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

NT$ 196.83M

NT$ 31.95
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1952 and headquartered in Tainan, Taiwan, Taiyen Biotech Co., Ltd. is a multifaceted enterprise engaged in the global production and distribution of salt-based goods. The company offers a wide-ranging portfolio that includes various salt and seawater-derived chemical products, alongside an array of personal care items such as bath salts, specialty soaps, and shampoos. Beyond hygiene products, their offerings extend to beverages, drinking water, and oral and optical care solutions like toothpaste, mouthwash, and contact lens maintenance fluids. Taiyen also provides specialized salts for cleaning produce, as well as food items and additives. Furthermore, the company manufactures pharmaceutical products, encompassing both cosmetic formulations and environmental health medications. Its operations also include the import and export of general consumer goods and beauty products, complemented by expert consulting services in industrial salt technology, covering supply, implementation, and management.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, r

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.07.2026 23:35

HSBC does not expect SpaceX's stock to rise. To value the stock, it had to abandon conventional methods.

24.07.2026 23:10

Freedom recommended buying Alphabet stock after the pullback. What could hinder its growth?

24.07.2026 22:45

Key Developments in the Kazakh Market: The Stakes of the Oil War and Signals from the National Bank

24.07.2026 22:34

"The Divorce of the Century": SK CEO to Pay Ex-Wife $643 Million but Retain Control of SK Hynix

24.07.2026 22:34

"The Divorce of the Century": SK CEO to Pay Ex-Wife $643 Million but Retain Control of SK Hynix

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026